As widely expected following a positive June advisory vote, the FDA gave its nod to Sprout Pharmaceuticals Inc.'s Addyi (flibanserin) as the first-ever therapeutic approved in the U.S. specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women.